These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1615101)

  • 1. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures.
    Hogan TP; Awad AG
    Psychol Med; 1992 May; 22(2):347-52. PubMed ID: 1615101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subjective response to neuroleptics in schizophrenia.
    Awad AG
    Schizophr Bull; 1993; 19(3):609-18. PubMed ID: 7901897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables.
    Mauri MC; Vita A; Giobbio GM; Ferrara A; Dieci M; Bitetto A; Altamura AC
    Int Clin Psychopharmacol; 1994; 9(1):3-7. PubMed ID: 8195579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of positive and negative symptom constructs during neuroleptic treatment in schizophrenia.
    Goldman RS; Tandon R; Liberzon I; Goodson J; Greden JF
    Psychopathology; 1991; 24(4):247-52. PubMed ID: 1754657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
    Tollefson GD; Sanger TM; Lu Y; Thieme ME
    Arch Gen Psychiatry; 1998 Mar; 55(3):250-8. PubMed ID: 9510219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of neuroleptic therapy in the self assessment of schizophrenic patients].
    Heim M
    Psychiatr Neurol Med Psychol (Leipz); 1987 Aug; 39(8):487-91. PubMed ID: 3685210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia.
    Hogan TP; Awad AG; Eastwood MR
    Can J Psychiatry; 1985 Jun; 30(4):246-8. PubMed ID: 2861887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement.
    Bartkó G; Herczeg I; Békésy M
    J Clin Psychiatry; 1987 Sep; 48(9):363-5. PubMed ID: 3624207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of 2 depression scales and their relationship with negative and akinetic symptoms in stabilized schizophrenic patients].
    Langlois-Thery S; Dollfus S; Lesieur P; Petit M
    Encephale; 1994; 20(5):487-93. PubMed ID: 7828511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
    Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
    Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subjective response to antipsychotic drugs: failure to replicate predictions of outcome.
    Ayers T; Liberman RP; Wallace CJ
    J Clin Psychopharmacol; 1984 Apr; 4(2):89-93. PubMed ID: 6707245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rating of medication influences (ROMI) scale in schizophrenia.
    Weiden P; Rapkin B; Mott T; Zygmunt A; Goldman D; Horvitz-Lennon M; Frances A
    Schizophr Bull; 1994; 20(2):297-310. PubMed ID: 7916162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total and free plasma neuroleptic levels in schizophrenic patients.
    Tang SW; Glaister J; Davidson L; Toth R; Jeffries JJ; Seeman P
    Psychiatry Res; 1984 Dec; 13(4):285-93. PubMed ID: 6596586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point.
    Van Putten T; May PR
    Arch Gen Psychiatry; 1978 Apr; 35(4):477-80. PubMed ID: 727898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two factors of experienced deficits in schizophrenia and their relationships with positive, negative, and depressive symptoms.
    Iwawaki A; Narushima K; Ota K; Okura T; Tsuchiya K; Takashima A
    Compr Psychiatry; 1998; 39(6):386-91. PubMed ID: 9829147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
    Reschke RW
    Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of drug responses in schizophrenia: a method using a test dose of chlorpromazine.
    Minami H; Nakahara T; Miyahara A; Nakane Y
    Psychiatry Clin Neurosci; 1997 Aug; 51(4):217-22. PubMed ID: 9316167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The measurement of subjective experience in schizophrenia: the Subjective Deficit Syndrome Scale.
    Jaeger J; Bitter I; Czobor P; Volavka J
    Compr Psychiatry; 1990; 31(3):216-26. PubMed ID: 2340716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
    Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
    Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.